JP2018525001A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018525001A5 JP2018525001A5 JP2018506183A JP2018506183A JP2018525001A5 JP 2018525001 A5 JP2018525001 A5 JP 2018525001A5 JP 2018506183 A JP2018506183 A JP 2018506183A JP 2018506183 A JP2018506183 A JP 2018506183A JP 2018525001 A5 JP2018525001 A5 JP 2018525001A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- nucleic acid
- permeable conjugate
- cell permeable
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims 25
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 18
- 108020004707 nucleic acids Proteins 0.000 claims 10
- 102000039446 nucleic acids Human genes 0.000 claims 10
- -1 phosphorothioate nucleic acid Chemical class 0.000 claims 10
- 229960002685 biotin Drugs 0.000 claims 9
- 235000020958 biotin Nutrition 0.000 claims 9
- 239000011616 biotin Substances 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 230000001225 therapeutic effect Effects 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 102000018697 Membrane Proteins Human genes 0.000 claims 3
- 108010052285 Membrane Proteins Proteins 0.000 claims 3
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 230000035699 permeability Effects 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 108090001008 Avidin Proteins 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 208000012239 Developmental disease Diseases 0.000 claims 1
- 208000017701 Endocrine disease Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 108091029810 SaRNA Proteins 0.000 claims 1
- 108091027967 Small hairpin RNA Proteins 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 108010090804 Streptavidin Proteins 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000030172 endocrine system disease Diseases 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 108091070501 miRNA Proteins 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 229940078677 sarna Drugs 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562201993P | 2015-08-06 | 2015-08-06 | |
| US62/201,993 | 2015-08-06 | ||
| PCT/US2016/045819 WO2017024239A1 (en) | 2015-08-06 | 2016-08-05 | Therapeutic cell internalizing conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018525001A JP2018525001A (ja) | 2018-09-06 |
| JP2018525001A5 true JP2018525001A5 (https=) | 2019-09-12 |
Family
ID=57943993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018506183A Pending JP2018525001A (ja) | 2015-08-06 | 2016-08-05 | 治療用細胞内在化コンジュゲート |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20180243436A1 (https=) |
| EP (1) | EP3331573A4 (https=) |
| JP (1) | JP2018525001A (https=) |
| CN (1) | CN108136042A (https=) |
| AR (1) | AR105641A1 (https=) |
| TW (1) | TW201718024A (https=) |
| WO (1) | WO2017024239A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016206475B2 (en) * | 2015-01-16 | 2021-11-04 | City Of Hope | Cell penetrating antibodies |
| EP3277811B1 (en) | 2015-04-03 | 2020-12-23 | University of Massachusetts | Fully stabilized asymmetric sirna |
| US10633653B2 (en) | 2015-08-14 | 2020-04-28 | University Of Massachusetts | Bioactive conjugates for oligonucleotide delivery |
| WO2017132669A1 (en) | 2016-01-31 | 2017-08-03 | University Of Massachusetts | Branched oligonucleotides |
| CA3033368A1 (en) | 2016-08-12 | 2018-02-15 | University Of Massachusetts | Conjugated oligonucleotides |
| JP7406793B2 (ja) | 2017-06-23 | 2023-12-28 | ユニバーシティー オブ マサチューセッツ | ２テイル自己デリバリー型ｓｉＲＮＡおよび関連方法 |
| CN111093710A (zh) * | 2017-07-13 | 2020-05-01 | 希望之城 | 硫代磷酸酯缀合的肽及其使用方法 |
| US11607457B2 (en) | 2017-07-13 | 2023-03-21 | City Of Hope | Anti-cancer phosphorothioate-coupled peptide conjugates and methods of using the same |
| JP7627042B2 (ja) | 2018-08-23 | 2025-02-05 | ユニバーシティー オブ マサチューセッツ | Ｏ－メチルリッチ完全安定化オリゴヌクレオチド |
| CN113614232A (zh) | 2019-01-18 | 2021-11-05 | 马萨诸塞大学 | 动态药代动力学修饰锚 |
| MX2022001710A (es) | 2019-08-09 | 2022-05-10 | Univ Massachusetts | Oligonucleótidos modificados químicamente dirigidos a los snp. |
| CA3147366A1 (en) * | 2019-08-14 | 2021-02-18 | Adam T. BOUTIN | Extracellular vesicles with stat3-antisense oligonucleotides |
| US12365894B2 (en) | 2019-09-16 | 2025-07-22 | University Of Massachusetts | Branched lipid conjugates of siRNA for specific tissue delivery |
| WO2021242883A1 (en) | 2020-05-26 | 2021-12-02 | University Of Massachusetts | Synthetic oligonucleotides having regions of block and cluster modifications |
| AU2022299169A1 (en) | 2021-06-23 | 2024-02-08 | Beth Israel Deaconess Medical Center, Inc. | Optimized anti-flt1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders |
| WO2024091824A1 (en) | 2022-10-26 | 2024-05-02 | Ada Forsyth Institute, Inc. | Differentiation and reprogramming of chondrocyte |
| EP4634373A1 (en) | 2022-12-16 | 2025-10-22 | University of Rochester | Repairment of barrier dysfunction in esophagus |
| WO2024151843A1 (en) * | 2023-01-11 | 2024-07-18 | The Johns Hopkins University | Targeted universal delivery system of don and other drugs |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ565075A (en) * | 2005-06-20 | 2011-05-27 | Psma Dev Company Llc | PSMA antibody-drug conjugates |
| WO2009012359A2 (en) * | 2007-07-17 | 2009-01-22 | The General Hospital Corporation | Matrix metalloprotease targeting nucleic acids |
| NZ602675A (en) * | 2008-03-18 | 2014-03-28 | Genentech Inc | Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
| US20110218334A1 (en) * | 2008-07-11 | 2011-09-08 | Alnylam Pharmaceuticals, Inc. | PHOSPHOROTHIOATE OLIGONUCLEOTIDES AND NON-NUCLEOSIDIC PHOSPHOROTHIOATES AS DELIVERY AGENTS FOR iRNA AGENTS |
| EP2681557A4 (en) * | 2011-03-04 | 2015-07-08 | Bio Rad Laboratories | SIGNAL REINFORCEMENT FOR IMMUNOASSAYS THROUGH AVIDIN BIOTIN BINDINGS |
| US10793913B2 (en) * | 2013-03-08 | 2020-10-06 | City Of Hope | Methods and compositions for treatment of breast cancer |
| CN111437395A (zh) * | 2013-08-29 | 2020-07-24 | 希望之城 | 细胞穿透缀合物及其使用方法 |
| JP2017505104A (ja) * | 2013-11-08 | 2017-02-16 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | インビボにおける薬剤送達のための核酸ナノ構造体 |
-
2016
- 2016-08-05 WO PCT/US2016/045819 patent/WO2017024239A1/en not_active Ceased
- 2016-08-05 EP EP16833942.2A patent/EP3331573A4/en not_active Withdrawn
- 2016-08-05 US US15/750,818 patent/US20180243436A1/en not_active Abandoned
- 2016-08-05 JP JP2018506183A patent/JP2018525001A/ja active Pending
- 2016-08-05 CN CN201680058474.9A patent/CN108136042A/zh active Pending
- 2016-08-05 TW TW105124955A patent/TW201718024A/zh unknown
- 2016-08-08 AR ARP160102424A patent/AR105641A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018525001A5 (https=) | ||
| Zheng et al. | Folate-displaying exosome mediated cytosolic delivery of siRNA avoiding endosome trapping | |
| Dassie et al. | Current progress on aptamer-targeted oligonucleotide therapeutics | |
| Kim et al. | Design and clinical developments of aptamer-drug conjugates for targeted cancer therapy | |
| Arnold et al. | Antibody-antisense oligonucleotide conjugate downregulates a key gene in glioblastoma stem cells | |
| Chen et al. | Nucleic acid aptamer application in diagnosis and therapy of colorectal cancer based on cell-SELEX technology | |
| Duangrat et al. | Tetrahedral DNA nanostructures as drug delivery and bioimaging platforms in cancer therapy | |
| Kruspe et al. | Aptamer-siRNA chimeras: discovery, progress, and future prospects | |
| Zhou et al. | Aptamers: A promising chemical antibody for cancer therapy | |
| Zhang et al. | A polyvalent aptamer system for targeted drug delivery | |
| Ray et al. | Aptamers for targeted drug delivery | |
| Mahlknecht et al. | Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth | |
| Guo et al. | Exosomes: Potent regulators of tumor malignancy and potential bio-tools in clinical application | |
| Yoon et al. | Targeted delivery of C/EBPα-saRNA by pancreatic ductal adenocarcinoma-specific RNA aptamers inhibits tumor growth in vivo | |
| Kanwar et al. | Chimeric aptamers in cancer cell-targeted drug delivery | |
| Shishparenok et al. | DNA-based nanomaterials as drug delivery platforms for increasing the effect of drugs in tumors | |
| Kruspe et al. | Aptamers as drug delivery vehicles | |
| Perche et al. | Hydroxychloroquine-conjugated gold nanoparticles for improved siRNA activity | |
| Xu et al. | Specific delivery of delta-5-desaturase siRNA via RNA nanoparticles supplemented with dihomo-γ-linolenic acid for colon cancer suppression | |
| JP2018525381A5 (https=) | ||
| Esposito et al. | Aptamer-mediated selective delivery of short RNA therapeutics in cancer cells | |
| JP2021167329A5 (https=) | ||
| CN107469088A (zh) | 一种基于dna折纸术的精确识别靶向纳米载体的构建方法及其应用 | |
| Li et al. | Nanoparticle-conjugated aptamer targeting hnRNP A2/B1 can recognize multiple tumor cells and inhibit their proliferation | |
| JP2006524242A5 (https=) |